13F Pro13F Pro

Eversept Partners, LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1697013
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare93.3%$1.7B
  • Real Estate5.9%$107.7M
  • Industrials0.8%$13.9M
  • Financials0.1%$872,206

AUM History

13fpro.ai/research/fund/eversept-partners-lp-1697013

Conviction and streaks

Diversifying · top 10 = 46.6%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

UTHR$UTHRConviction hold8.5% weight · held 10 quartersABVX$ABVXConviction hold6.6% weight · held 4 quartersVERA$VERAConviction hold5.2% weight · held 10 quartersCLDX$CLDXConviction hold3.6% weight · held 10 quartersSNDX$SNDXConviction hold3.3% weight · held 10 quartersVKTX$VKTXAccumulating+2542% shares · 3 quarters runningPODD$PODDAccumulating+226% shares · 3 quarters runningPNTG$PNTGAccumulating+1112% shares · 3 quarters runningCTNM$CTNMAccumulating+10% shares · 3 quarters runningUTHR$UTHRAccumulating+14% shares · 2 quarters runningSNDX$SNDXTrimming-34% shares · 5 quarters runningRVTY$RVTYTrimming-84% shares · 4 quarters runningPCVX$PCVXTrimming-56% shares · 3 quarters runningNAMS$NAMSTrimming-44% shares · 3 quarters runningTECH$TECHTrimming-97% shares · 3 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/eversept-partners-lp-1697013

Eversept Partners, LP 13F holdings — Q2 2026

$1.9B portfolio (+1.6% QoQ) · 120 holdings · Q2 2026 13F · top 10 are 47% of the stock portfolio

Includes $93.3M of put/call options ($80.3M puts, $13.0M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $1.8B. Weights use the stock portfolio.

All holdings — Eversept Partners, LP (Q2 2026)

120 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
QQQ$QQQPUTINVESCO QQQ TRUST, SERIES 1$72.6M-59%
TVTX$TVTXTravere Therapeutics, Inc.$45.4M+47%
CTRE$CTRECareTrust REIT, Inc.$43.3MNew
HCA$HCAHCA Healthcare, Inc.$38.3M+24%
PCVX$PCVXVaxcyte, Inc.$36.6M-32%
LQDA$LQDALiquidia Corp$34.2M-37%
CYH$CYHCOMMUNITY HEALTH SYSTEMS INC$26.3M-9%
GSK$GSKGSK plcadr$25.3M-73%
CHE$CHECHEMED CORP$24.5M+69%
LLY$LLYELI LILLY & Co$24.1M+6%
GERN$GERNGERON CORP$24.0M-0.6%
VKTX$VKTXViking Therapeutics, Inc.$23.5M+152%
OHI$OHIOMEGA HEALTHCARE INVESTORS INC$23.1M-17%
PODD$PODDINSULET CORP$22.7M+4%
THC$THCTENET HEALTHCARE CORP$21.4M+287%

What changed in Q2 2026

Against the previous quarter's 13F: 31 new, 40 added to, 42 trimmed, 31 sold out. Share-count changes; largest moves by dollar size first.

New positions (31)

  • CTRE$CTRECareTrust REIT, Inc.$43.3M

    first bought this quarter

  • UNH$UNHUNITEDHEALTH GROUP INC$21.3M

    first bought this quarter

  • COGT$COGTCogent Biosciences, Inc.$19.0M

    first bought this quarter

  • INSM$INSMINSMED Inc$15.9M

    first bought this quarter

  • AMN$AMNAMN HEALTHCARE SERVICES INC$13.9M

    first bought this quarter

  • CELC$CELCCelcuity Inc.$13.4M

    first bought this quarter

+25 more in the Excel export

Added to (40)

  • ENSG$ENSGENSIGN GROUP, INC+3979%

    now $96.5M · held 2 qtrs, 2 adds in a row

  • EHC$EHCEncompass Health Corp+429%

    now $103.8M · held 3 qtrs, 3 adds in a row

  • THC$THCTENET HEALTHCARE CORP+287%

    now $21.4M · held 2 qtrs, 2 adds in a row

  • TVTX$TVTXTravere Therapeutics, Inc.+47%

    now $45.4M · held 5+ qtrs

  • VKTX$VKTXViking Therapeutics, Inc.+152%

    now $23.5M · held 2 qtrs, 2 adds in a row

  • UTHR$UTHRUNITED THERAPEUTICS Corp+9%

    now $155.9M · held 5+ qtrs, 2 adds in a row

+34 more in the Excel export

Trimmed (42)

  • QQQ$QQQPUTINVESCO QQQ TRUST, SERIES 1-59%

    now $72.6M

  • GSK$GSKGSK plc-73%

    now $25.3M · held 5+ qtrs, 2 trims in a row

  • NTRA$NTRANatera, Inc.-54%

    now $47.7M · held 5+ qtrs

  • WELL$WELLWELLTOWER INC.-52%

    now $19.8M · held 2 qtrs

  • LQDA$LQDALiquidia Corp-37%

    now $34.2M · held 5+ qtrs

  • PCVX$PCVXVaxcyte, Inc.-32%

    now $36.6M · held 5+ qtrs, 3 trims in a row

+36 more in the Excel export

Sold out (31)

  • SPY$SPYPUTSPDR S&P 500 ETF TRUSTwas $69.6M
  • VRTX$VRTXCALLVERTEX PHARMACEUTICALS INC / MAwas $40.2M
  • PUTISHARES TRwas $37.2M
  • DOC$DOCHEALTHPEAK PROPERTIES, INC.was $32.5M

    held 1 qtr

  • AVTR$AVTRAvantor, Inc.was $23.3M

    held 9+ qtrs

  • QGEN$QGENQIAGEN N.V.was $21.8M

    held 1 qtr

+25 more in the Excel export

Firm AUM (Form ADV): $2.7B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Eversept Partners, LP has filed, 33 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Eversept Partners?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Eversept Partners's top 20 holdings: 56/100 (our AI quality score, weighted by position size; 15 of the 20 are scored)

Top 10 since filing

-7.8%

Value-weighted move of the 10 largest stock positions

Turnover

24%

Last quarter; 89% over the last 4

Top 10 weight

47%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

56%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q2 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Eversept Partners, LP disclosed 120 positions worth $1.9B in its Form 13F-HR for Q2 2026 — $1.8B in common stock plus $93.3M of put/call option positions (reported at underlying notional value, not premium at risk), led by $UTHR (UNITED THERAPEUTICS Corp) at 8.5% of the equity portfolio, followed by $ABVX and $EHC. During the quarter the fund opened 31 new positions and exited 31 — including a new stake in $CTRE and a full exit from $SPY. The portfolio is most concentrated in Healthcare (93.3% of disclosed assets). All figures are sourced directly from Eversept Partners, LP’s Form 13F-HR filing with the SEC under CIK 1697013.

Funds like this

managers whose biggest positions overlap Eversept Partners's
Kynam Capital Management, LP$1.81B 13F book · 12 shared top holdingsVERACLDXSNDXTVTXDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)$9.59B 13F book · 10 shared top holdingsIONSUTHRBKDVERAVestal Point Capital, LP$4.28B 13F book · 8 shared top holdingsABVXUTHRPODDBCRXAvoro Capital Advisors LLC$11.14B 13F book · 4 shared top holdingsUTHRVERACELCVRDNDeep Track Capital, LP$6.87B 13F book · 8 shared top holdingsIONSVERAPCVXCLDXElmind Capital, LP$398.03M 13F book · 13 shared top holdingsVERACLDXSNDXTVTX

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Eversept Partners, LP

13F Pro is an AI hedge fund tracker and stock research platform. For Eversept Partners, LP (SEC CIK: 1697013), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Eversept Partners, LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.